ESMO 2023

Preoperative checkpointinihition in ER+ disease

Remarkable efficacies in patients with HER2+ mBC with brain metastases

My highlights of ESMO23 in metastatic breast cancer

5 year follow-up

DATO-DX - where is it going?

Highlights in eBC

Early use of enzalutamide in advanced prostate cancer

The FGFR story in bladder cancer at ESMO23

Clearing up non-clear cell RCC

New 3rd line therapy for RCC

When the history of ADC is written: Redefining first-line standard of care in mUC!

Lu-PSMA leads forward

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

ALINA - immediate change of practice!

Tarlatamab in SCLC

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

My highlights from ESMO 2023

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

What is your definition of triple-negative breast cancer?

What was the most exciting news at ESMO23?

Data updates for CDK4/6 inhibitors in EBC at ESMO23 - implications for clinical practice

New and better biomarkers are needed!

Anticipated updates and exciting new data for checkpointinhibitors

5 year follow-up

Consolidation of data in early HR+ and triple-negative breast cancer

Metabolomics reveal differential expression of OMEGA 3 & OMEGA 6 in neoadjuvant treatment

Detailed view of nodal-negative patients

Negative EFS results from NeoTrip

MonarchE - trial update

Pembrolizumab solidifies as SOC in early-stage TNBC

ER-low corresponds diagnostically to ER-0 breast cancer

HR+ study with > 20 % PCR

Prognostic score in early HR+/HER2-BC: translational data from ADAPT

Preoperative checkpointinihition in ER+ disease

Use of immunotherapy in the perioperative setting of luminal Her2- BC

Ribociclib effective in all subtypes

Neoadjuvant IO - is their new strategy in HR+ breast cancer

Analysis of tumour microenvironment and immunophenotype in TNBC

Immunoncology in eBC - triple negative and more?

New data on neoadjuvant immunotherapy

My highlights of ESMO23 in early breast cancer

Clinically relevant effect of pembro also in PCR

Our guidelines are correct

Carry-over effects in monarchE confirmed

Highlights in eBC

Studio NeoTrip: negativi i risultati

Nouvelles données sur l'immunothérapie néoadjuvante

Punti salienti in eBC

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6 nel condizionare la risposta alla terapia neo-adiuvante

MonarchE - mise à jour de l'essai

New ADC for metastatic breast cancer?

Improvement of therapy outcome by app-based patient education

ADCs in HER2+, HER2low and TNBC - what is the future of ADCs?

What was the most exciting news at ESMO23?

How to organize a molecular tumorboards in breast cancer?

New targets, new linker, new ADCs - much more to learn with new therapies!

HS20089 - a novel ADC is coming for TNBC

Our guidelines are correct

TROP2 expression as a potential mechanism of resistance in HER2+ patients

T-DXd - new standard of care for brain mets?

TULIP: Trastuzumab duocarmazine without OS benefit

Improved oncological therapy with the smartphone

Remarkable efficacies in patients with HER2+ mBC with brain metastases

ADC + Immunotherapy - the BEGONIA study paradigm

Duvalumab + Dato-DXd effective

Fulvestran better than anastrozole, but no survival benefit

OP-1250 (Palezestrant) confirms the role of SIRDs after CDK4/6i

Benefit for SG even after intensive pretreatment

DATO-DX - where is it going?

New ADC in HR+ disease

HER2DX in the PHERgain trial

Even more new generation ADCs in breast cancer?

My highlights of ESMO23 in metastatic breast cancer

Still on track for success in HER2-low MBC

Dato-DXd - new player in advanced luminal disease

Robust data from the monarchE

Abemaciclib remains consistent in 5-year follow-up

T-DXd in HER2+ patients with brain metastases

Can surgery be spared following primary systemic therapy?

T-DXd also effective for brain metastases

Highlights in mBC

Patient-centered molecular medicine - a new approach

OP seems to be dispensable for super responders

Punti salienti in mBC

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei SERDs dopo le cicline

La expresión de TROP2 como potencial mecanismo de resistencia en pacientes HER2+.

T-DXd - nowy standard postępowania w przerzutach do mózgu?

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par le cancer triple negative

HS20089 - un nuovo ADC che si affaccia sulla scenda del TNBC

HER2DX en el estudio PHERgain

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

Lo studio BEGONIA nelle paziento con tumore triplo negativo

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym leczeniu systemowym?

The optimal timing of RT after radical prostatectomy and QoL data of ENZA therapy in nmHSPC

What is the future of immune therapy in prostate cancer?

Targeted therapy will move forward - but more robust data is needed.

Should we use zoledronic acid in all ADT patients?

Brave New World in mCRPC

PSMAfore unleashes urooncologic opportunity

Combination of radioligand therapy with chemotherapy useful

TITAN: ultra-low PSA = best prognosis

EMBARK expands ENZA indication to PCa

Early use of enzalutamide in advanced prostate cancer

Longterm toxicity of adjuvant RT after prostatectomy

STAMPEDE. Bone prediction not for everyone - better risk stratification for PCa

Salvage radiotherapy the new standard

When immunotherapy is probably not the best choice: The case of untreated metastatic prostate cancer

EMBARK - Quality of Life

Immunotherapy in metastatic PCa

Precision medicine at mCRCP

IO therapy in metastatic prostate cancer.

PSMA FORE: Trial and controversies

Lu-PSMA leads forward

RADICALS RT: Trial and controversies

Big data and AI prediction tools

Negative data for pembrolizumab in mHSCPC & mCRPC

Osteoprotection at mHSPC

ENZA P:Trial and controversies

Embark without fear

CXCR2 inhibitor in PCa

EMBARK och livskvalitet

STAMPEDE data. Skelettstärkande och riskstratifiering.

Big Data och AI för prediktion vid prostatacancer

CXCR2 hämmare och prostatacancer

Immunterapi vid prostatacancer

Cuando la inmunoterapia probablemente no es la mejor elección: El caso del cancer de próstata avanzado en pacientes no seleccionados

Part 2: New standard of care in first line urothelial cancer!

FGFR inhibitors and ADC combinations in urothelial cancer - new options for the future?!

Part1: New standard of care in first line urothelial cancer?!

Unique bladder delivery system of gemcitabine herolds remarkable response

Chemo-IO establishes itself in the first-line treatment of bladder cancer

FGFR inhibitors: What is the best scenario for this family of compounds?

When the history of ADC is written: Redefining first-line standard of care in mUC!

New SoC in firstline bladder cancer

EV + Pembro as standard of care in first-line therapy of bladder cancer

DAD, DAD-IO

The FGFR story in bladder cancer at ESMO23

Amazing new data in bladder cancer

Reescribiendo la historia de una enfermedad: Nuevo estándar de tratamiento en primera linea en cancer urotelial avanzado

Inhibidores de FGFR: Cual es el mejor escenario para esta familia de fármacos?

Στιγμιότυπα για τον καρκίνο των νεφρών και της ουροδόχου κύστης στο ESMO23

L'histoire du FGFR dans le cancer de la vessie à l'ESMO23

Important new treatment option but only for subset of patients?

Is de-escalating therapy ready for prime-time?

Where does the future therapy go in renal cell carcinoma?

New 3rd line therapy for RCC

Belzutifan - whats next kidney cancer?

Kidney cancer highlights at ESMO23

Clearing up non-clear cell RCC

New mode of action in mRCC - ready for prime time?

Intermittent therapy also possible with TKIs

Belzutifan in later lines of therapy

ALINA - remarkably positive DFS in early-stage ALK+ NSCLC

Moving patients to the neoadjuvant setting in non-metastatic NSCLC

Neoadjuvant chemo-immunotherapy new standards in early & advanced NSCLC

Perioperative IO: OS-benefi from KEYNOTE-671

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Scene is set for inductive immunotherapy

Adjuvant alectinib in patients with early-stage ALK+ NSCLC

ALINA - immediate change of practice!

Circulating DNA in AEGEAN trial

Substantial improvement in local regional NSCLC

My highlights from ESMO 2023

ALINA - a new paradigm in operated NSCLC with ALK-fusion

Big improvements in early stage and a subset of metatstic NSCLC

I miei punti salienti di ESMO 2023

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

ALINA - un nouveau paradigme dans cBNPC avec la fusion ALK

Perioperatieve chemo-immunotherapie voor alle patienten met resectabel stadium II-IIIB NSCLC?

Les points forts de l'ESMO 2023

Activating EGFR-mutation - what's coming up?

Rare oncogenic alterations: landmark results on exon 20 insertion & confirming data on RET fusion+ NSCLC

ESMO2023-impact on everyday practice!

Evolving landscape of ADCs

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Brain metastases – options to improve the systemic treatment

Changing treatment landscape in EGFR-mutated NSCLC

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

Big improvements in early stage and a subset of metatstic NSCLC

Do ADCs have brain activity?

By unanimous decision and still the champion – docetaxel!

Amivantamab at progression? MARIPOSA-2 trial

Adagrasib + pembrolizumab in patients with KRASG12C mutation

PAPILLON - bringing together therapy for the 1st line

MARIPOSA: Trial and controversies

MARIPOSA II: Trial and controversies

New standard of care for metastatic EGFR exon 20 insertion mutated NSCLC

Treatment sequences for EGFR-mutated Patients

TROPION-Lung01: positive development

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

NRG fusions: a new drugable target?

Substantial improvement in rare alterations

Does immunotherapy still have a place in EGFR-positive mNSCLC?

LIBRETO - a positive study, but was it necessary?

Amivantamab upfront? MARIPOSA trial

Practice changing results on exon 20 insertion mNSCLC

My highlights from ESMO 2023

L’amivantamab, nouveau standard de traitement pour les EGFR exon 20

Amivantamab upfront? MARIPOSA trial

Amivantamab at progression? MARIPOSA-2 trial

Veränderte Behandlungslandschaft bei EGFR-mutiertem NSCLC

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Heeft immunotherapie nog een plek in de behandeling van EGFR-positief gemetastaseerd NSCLC?

I miei punti salienti di ESMO 2023

Nieuwe standaard voor gemetastaseerd EGFR exon20 insertie gemuteerd NSCLC

Les points forts de l'ESMO 2023

Quelles séquences thérapeutiques pour les patients EGFR mutés

Impact of T-cell engagers in SCLC

New hope for patients with SCLC

A new option in relapsed SCLC

Tarlatamab in SCLC

Neue Hoffnung für Patienten mit SCLC

Update on gynaecological cancers

PCO Therapeutics

First data on luveltamab in multiline treatment for endometrial cancer

Precision oncology in CUP

New data on H&N Cancer

Evolution of the revolution - the RUBY trial

New data on sarkomas